Major Japanese Drug Makers Jointly Apply For Additional Indications For H. Pylori Combo Therapy
This article was originally published in PharmAsia News
Executive SummaryNine Japanese drug makers of proton pump inhibitors and antibiotic drugs Oct. 1 jointly applied for additional indications for combination therapy of the agents to eradicate helicobacter pylori
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.